Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease : A Systematic Review

Show full item record



Permalink

http://hdl.handle.net/10138/307426

Citation

Boertien , J M , Pereira , P A B , Aho , V T E & Scheperjans , F 2019 , ' Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease : A Systematic Review ' , Journal of Parkinson's disease , vol. 9 , pp. S297-S312 . https://doi.org/10.3233/JPD-191711

Title: Increasing Comparability and Utility of Gut Microbiome Studies in Parkinson's Disease : A Systematic Review
Author: Boertien, Jeffrey M.; Pereira, Pedro A. B.; Aho, Velma T. E.; Scheperjans, Filip
Contributor: University of Helsinki, Institute of Biotechnology
University of Helsinki, HUS Neurocenter
University of Helsinki, HUS Neurocenter
Date: 2019
Language: eng
Number of pages: 16
Belongs to series: Journal of Parkinson's disease
ISSN: 1877-7171
URI: http://hdl.handle.net/10138/307426
Abstract: Gut microbiota have been studied in relation to the pathophysiology of Parkinson's disease (PD) due to the early gastrointestinal symptomatology and presence of alpha-synuclein pathology in the enteric nervous system, hypothesized to ascend via the vagal nerve to the central nervous system. Accordingly, sixteen human case-control studies have published gut microbiome composition changes in PD and reported over 100 differentially abundant taxa covering all taxonomic levels from phylum to genus or species, depending on methodology. While certain findings were replicated across several studies, various contradictory findings were reported. Here, differences in methodologies and the presence of possible confounders in the study populations are assessed for their potential to confound the results of gut microbiome studies in PD. Gut microbiome studies in PD exhibited considerable variability with respect to the study population, sample transport conditions, laboratory protocols and sequencing, bioinformatics pipelines, and biostatistical methods. To move from the current heterogeneous dataset towards clinically relevant biomarkers and the identification of putative therapeutic targets, recommendations are derived from the limitations of the available studies to increase the future comparability of microbiome studies in PD. In addition, integration of currently available data on the gut microbiome in PD is proposed to identify robust gut microbiome profiles in PD. Furthermore, expansion of the current dataset with atypical parkinsonism cohorts, prodromal and treatment naive de novo PD subjects, measurements of fecal microbial concentrations and multi-omics assessments are required to provide clinically relevant biomarkers and reveal therapeutic targets within the gut microbiome of PD.
Subject: Parkinson disease
gut microbiome
case-control studies
systematic review
POPULATION
INFLAMMATION
ASSOCIATION
DYSFUNCTION
DIAGNOSIS
VAGOTOMY
CRITERIA
REVEALS
GENOME
MODEL
3112 Neurosciences
3124 Neurology and psychiatry
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
jpd_9_jpd191711.pdf 761.6Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record